ACE inhibitors

References

• The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1988: 148(5): 1023–38
   PubMedGoogle Scholar
• Amadio P Jr, Cummings DM, Amadio PB. Tailoring the antihypertensive drug regimen. Am Fam Physician 1986: 34(2): 157–70 [errata, Am Fam Physician 1987: 35(1): 26: 1987: 35(6): 49: 1987: 36(1): 51]
   PubMed Web of Science ®Google Scholar
• Buhler FR, Bolli P, Kiowski W, et al. Renin profiling to select antihypertensive baseline drug: renin inhibitors for high-renin and calcium entry blockers for low-renin patients. Am J Med 1984: 77(2A): 36–42
   PubMed Web of Science ®Google Scholar
• Kostis JB, DeFelice EA, eds. Angiotensin converting enzyme inhibitors. New York: Alan R Liss, 1987: iX
   Google Scholar
• Drayer JI, Weber MA. Monotherapy of essential hypertension With a converting-enzyme inhibitor. Hypertension 1983: 5(5 Pt 2): II 108–13
   Google Scholar
• Yodfat Y, Fidel J, Bloom DS. Captopril as a replacement for multiple therapy in hypertension: a controlled study. J Hypertens Suppl 1985: 3(2): S155–8
   PubMedGoogle Scholar
• Jenkins AC, Knill JR, Dreslinski GR. Captopril in the treatment of the elderly hypertensive patient. Arch Intern Med 1985: 145(11): 2029–31
   PubMedGoogle Scholar
• Laragh JH. Modern system for treating high blood pressure based on renin profiling and vasoconstriction-volume analysis: a primary role for beta blocking drugs such as propranolol. Am J Med 1976: 61(5): 797–810
   PubMed Web of Science ®Google Scholar
• Holland OB, Gomes-Sanchez C, Fairchild C, et al. Role of renin classification for diuretic treatment of black hypertensive patients. Arch Intern Med 1979: 139(12): 1365–70
   PubMedGoogle Scholar
• Petrillo EW Jr, Ondetti MA. Angiotensin converting enzyme inhibitors: medicinal chemistry and biological actions. Med Res Rev 1982: 2(1): 1–41
   PubMed Web of Science ®Google Scholar
• Wyvratt MJ, Patchett AA. Recent developments in the design of angiotensin-converttng enzyme inhibitors. Med Res Rev 1985: 5(4): 483–531
   PubMed Web of Science ®Google Scholar
• Winter ME, Katcher BS, Koda-Kimble MA. Basic clinical pharmacokinetics. San Francisco: Applied Therapeutics. 1980: 209–13
   Google Scholar
• Given BD, Taylor T, Hollenberg NK, et al. Duration of action and short-term hornmonal responses to enalapril (MK 421) in normal subjects. J Cardiovasc Pharmacol 1984: 6(3): 436–41
   PubMed Web of Science ®Google Scholar
• Giudicelli JF, Berdeaux A, Edouard A, et al. The effect of enalapril on baroreceptor mediated reflex function in normotensive subjects. Br J Clin Pharmacol 1985: 20(3): 211–8
   PubMed Web of Science ®Google Scholar
• Weinberger MH. Role of sympathetic nervous system activity in the blood pressure response to long-term captopril therapy in severely hypertensive patients. Am J Cardiol 1982: 49(6): 1542–3
   PubMed Web of Science ®Google Scholar
• Dzau VJ, Colucci WS, Williams GH, et al. Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. N Engl J Med 1980: 302(25): 1373–9
   PubMed Web of Science ®Google Scholar
• Dunn FG, Oigman W, Ventura HO, et al. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular maas in essential hypertension. Am J Cardiol 1984: 53(1): 105–8
   PubMed Web of Science ®Google Scholar
• Packer M, Lee WH, Yushak M. et al. Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med 1986: 315(14): 847–53 [erratum, N Engl J Med 1986: 315(17): 1105]
   PubMed Web of Science ®Google Scholar
• Herrera-Acosta J, Perez-Grovas H, Fernandez M. et al. Enalapril in essential hypertension. Drugs 1985: 30(Suppl 1): 35–46
   PubMedGoogle Scholar
• Weber MA. The renin-angiotensin-aldosterone system and hypertension. In: Kostis, DeFelice, eds,4 pp 55–92
   Google Scholar
• Kaplan NM, Lieberman E. Clinical hypertension. 4th ed. Baltimore: Williams & Wllkins, 1986
   Google Scholar
• Williams GH, Hollenberg NK. Converting enzyme inhibitors normalize the reduced adrenal responsiveness to angiotensin II in essential hypertension. J Hypertens Suppl 1984: 2(2): S43–7
   Google Scholar
• Laragh JH, Case DB, Atlas SA, et al. Captopril compared with other antirenin system agents in hypertensive patients: its triphasic effects on blood pressure and its use to identify and treat the renin factor. Hypertension 1980: 2(4): 586–93
   PubMed Web of Science ®Google Scholar
• Laragh JH. Atrial natriuretic hormone, the renin- aldosterone axis, and blood pressure—electrolyte homeostasis. N Engl J Med 1985: 313(21): 1330–40
   PubMed Web of Science ®Google Scholar
• Gavras I, Gavras H. The use of ace inhibitors in hypertension. In: Kostis, DeFelice, eds,4 pp 93–122
   Google Scholar
• Laragh JH. Personal views on mechanisms of hypertension. In: Genest J, Koiw E, Kuchel O, eds. Hypertension: physiopathology and treatment. 2d ed. New York: McGraw-Hill, 1983: 615–52
   Google Scholar
• Hricik DE, Browning PJ, Kopelman R, et al. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. N Engl J Med 1983: 308(7): 373–6
   PubMed Web of Science ®Google Scholar
• Hollenberg NK. Angiotensin-converting enzyme inhibition: renal aspect. J Cardiovasc Pharmacol 1985: 7(Suppl 1): S40–4
   Google Scholar
• Curtiss C, Cohn JN, Vrobel T, et al. Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation 1978: 58(5): 763–70
   PubMed Web of Science ®Google Scholar
• Gavras H, Flessas A, Ryan TJ, et al. Angiotensin II inhibition: treatment of congestive cardiac failure in high-renin hypertension. JAMA 1977: 238(8): 880–2
   PubMed Web of Science ®Google Scholar
• Levine TB, Franciosa JA, Cohn JN. Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure. Circulation 1980: 62(1): 35–41
   PubMed Web of Science ®Google Scholar
• Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 1983: 2(4): 755–63
   PubMed Web of Science ®Google Scholar
• Kluger J, Cody RJ, Laragh JH. The contributions of sympathetic tone and the renin-angiotensin system to severe chronic congestive heart failure: response to specific inhibitors (prazosin and captopril). Am J Cardiol 1982: 49(7): 1667–74
   PubMed Web of Science ®Google Scholar
• Ferrario CBS, Dickinson CJ, McCubbin JW. Central vasomotor stimulation by angiotensin. Clin Sci 1970: 39(2): 239–45
   PubMed Web of Science ®Google Scholar
• Packer M, Medina N, Yushak M, et al. Hemodynamic patterns of response during long-term captopril therapy for severe chronic heart failure. Circulation 1983: 68(4): 803–12
   PubMed Web of Science ®Google Scholar
• Dzau VJ. Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 1988: 77(6 Pt 2): 14–13
   Google Scholar
• Magnani B, Magelli C. Captopril in mild heart failure: preliminary observations of a long-term, double-blind, placebo-controlled multicentre trial. Postgrad Med J 1986: 62(Suppl 1): 153–8
   PubMedGoogle Scholar
• Pfeffer MA, Lamas GA, Vaughan DE, et al. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 1988: 319(2): 80–6
   PubMed Web of Science ®Google Scholar
• Sharpe N, Murphy J, Smith H, et al. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1988: 1(8580): 255–9
   PubMed Web of Science ®Google Scholar
• Lund-Johansen P, Omvik P. Long-term haemodynamic effects of enalapril (alone and in combination with hydrochlorothiazide) at rest and during exercise in essential hypertension. J Hypertens Suppl 1984: 2(2): S49–56
   Google Scholar
• Veterans Administration Cooperative Study Group on Antihypertensive Agents. Captopril: evaluation of low doses, twice daily doses, and the addition of diuretic for the treatment of mild to moderate hypertension. Clin Sci 1982: 63: 443–5S
   Web of Science ®Google Scholar
• Brouwer RM, Bolli P, Erne P, et al. Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics. J Cardiovasc Pharmacol 1985: 7(Suppl 1): S88–91
   Google Scholar
• White WB, Viadero JJ, Lane TJ, et al. Effects of combination therapy with captopril and nifedipine in severe or resistant hypertension. Clin Pharmacol Ther 1986: 39(1): 43–8
   PubMed Web of Science ®Google Scholar
• MacGregor GA, Markandu ND, Smith SJ, et al. Captopril: contrasting effects of adding hydrochlorothiazide, propranolol, or nifedipine. J Cardiovasc Pharmacol 1985: 7(Suppl 1): S82–7
   Google Scholar
• Staessen J, Fagard R, Lijnen P, et al. Double-blind comparison between propranolol and bendroflumethiazide in captopril-treated resistant hypertensive patients. Am Heart J 1983: 106(2): 321–8
   PubMed Web of Science ®Google Scholar
• Bjorck S, Nyberg G, Mulec H, et al. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. BMJ (Clin Res) 1986: 293(6545): 471–4
   PubMed Web of Science ®Google Scholar
• Hommel E, Parving HH, Mathiesen E, et al. Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. BMJ (Clin Res) 1986: 293(6545): 467–70
   PubMed Web of Science ®Google Scholar
• Parving HH, Andersen AR, Smidt UM, et al. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983: 1(8335): 1175–9
   PubMed Web of Science ®Google Scholar
• Parving HH, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by captopril in insulin-dependent diabetics with nephropathy. BMJ (Clin Res) 1988: 297: 1086–91
   PubMed Web of Science ®Google Scholar
• Ventura HO, Frohlich ED, Messerli FH, et al. Cardiovascular effects and regional blood flow distribution associated with angiotensin converting enzyme inhibition (captopril) in essential hypertension. Am J Cardiol 1985: 55(8): 1023–6
   PubMed Web of Science ®Google Scholar
• Muller FB, Sealey JE, Caae DB, et al. The captopril test for identifying renovascular disease in hypertensive patients. Am J Med 1986: 80(4): 633–44
   PubMed Web of Science ®Google Scholar
• Fries JF, Wasner C, Brown J, et al. A controlled trial of antihypertensive therapy in systemic sclerosis (scleroderma). Ann Rheum Dis 1984: 43(3): 407–10
   PubMed Web of Science ®Google Scholar
• Thibonnier M, Joseph A, Plovin PF, et al. Diagnostic value of a single dose of captopril in renin and aldosterone dependent, surgically curable hypertension. Cardiovasc Rev Rep 1982: 3: 1659–68
   Google Scholar
• Mimran A, Targhetta R. Captopril treatment of idiopathic edema. (Letter) N Engl J Med 1979: 301(23): 1289–90
   PubMed Web of Science ®Google Scholar
• Wood LJ, Goergen S, Stockigt JR, et al. Adverse effects of captopril in treatment of resistant ascites, a state of functional bilateral renal artery stenosis. (Letter) Lancet 1985: 2(8462): 1008–9
   PubMed Web of Science ®Google Scholar
• De Venuto G, Andreotti C, Mattarei M, et al. Long-term captopril therapy at low doses reduces albumin excretion in patients with essential hypertension and no sign of renal impairment. J Hypertens Suppl 1985: 3(2): S143–5
   Google Scholar
• Taguma T, Kitamoto T, Futaki G, et al. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 1985: 313(26): 1617–20
   PubMed Web of Science ®Google Scholar
• Raij L, Chiou XC, Owens R, et al. Therapeutic implications of hypertension-induced glomerular injury: comparison of enalapril and a combination of hydralazine, reserpine, and hydrochlorothiazide in an experimental model. Am J Med 1985: 79(3C): 37–41
   PubMed Web of Science ®Google Scholar
• Strozzi C, Cocco G, Portaluppl F, et al. Ergometric evaluation of the effects of captopril in hypertensive patients with stable angina. J Hypertens Suppl 1985: 3(2): S147–8
   Google Scholar
• Reske SN, Heck I, Kropp J, et al. Captopril mediated decrease of aortic regurgitation. Br Heart J 1985: 54(4): 415–9
   PubMedGoogle Scholar
• Jarden JO, Barry DL, Juhler M, et al. Cerebrovascular aspects of converting-enzyme inhibition. II. Blood-brain barrier permeability and effect of intracerebroventricular administration of captopril. J Hypertens 1984: 2(6): 599–604
   PubMedGoogle Scholar
• Warren SE, O'Connor DT, Cohen IM. Autonomic and baroreflex function after captopril in hypertension. Am Heart J 1983: 105(6): 1002–8
   PubMed Web of Science ®Google Scholar
• Cody RJ. Haemodynamic responses to specific renin-angiotensin inhibitors in hypertension and congestive heart failure: a review. Drugs 1984: 28(2): 144–69
   PubMed Web of Science ®Google Scholar
• Rubin PC, Millar JA, Sturani S, et al. The influence of naloxone on the circulatory effects of captopril. Br J Clin Pharmacol 1984: 17(6): 713–7
   PubMed Web of Science ®Google Scholar
• Paulson OB, Jarden JO, Godtfredsen J, et al. Cerebral blood flow in patients with congestive heart failure treated with captopril. Am J Med 1984: 76(5B): 91–5
   PubMed Web of Science ®Google Scholar
• Anderson S, Meyer TW, Rennke HG, et al. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin invest 1985: 76(2): 612–9
   PubMed Web of Science ®Google Scholar
• Meggs LG, Hollenberg NK. Converting enzyme inhibition and the kidney. Hypertension 1980: 2(4): 551–7
   PubMed Web of Science ®Google Scholar
• Zusman RM. Renin and non-renin-mediated antihypertensive actions of converting enzyme inhibitors. Kidney Int 1984: 25(6): 969–83
   PubMed Web of Science ®Google Scholar
• Oliveri R. Effects of different antihypertensive drugs on left ventricular function. Drugs 1988: 35(Suppl 6): 83–9
   PubMedGoogle Scholar
• Erti G, Kloner RA, Alexander RW, et al. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation 1982: 65(1): 40–8
   PubMed Web of Science ®Google Scholar
• Hock CE, Ribeiro LG, Lefer AM. Preservation of ischemic myocardium by a new converting enzyme inhibitor, enalaprilic acid, in acute myocardial infarction. Am Heart J 1985: 109(2): 222–8
   PubMed Web of Science ®Google Scholar
• Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986: 314(26): 1657–64
   PubMed Web of Science ®Google Scholar
• Applefeld MM. Chronic congestive heart failure: Where have we been? Where are we heading? Am J Med 1986: 80(2B)73–7
   PubMed Web of Science ®Google Scholar
• Ferguson RK, Vlasses PH, Rotmensch HH. Clinical applications of angiotensin-converting enzyme inhibitors. Am J Med 1984: 77(4): 690–8
   PubMed Web of Science ®Google Scholar
• Vlasses PH, Ferguson RK, Chatterjee K. Captopril: clinical pharmacology and benefit-to-risk ratio in hypertension and congestive heart failure. Pharmacotherapy 1982: 2(1): 1–17
   PubMed Web of Science ®Google Scholar
• Physicians' desk reference. Oradell, NJ: Medical Economics, 1989
   Google Scholar